Acorda shares tank as appeals court refuses injunction against cheap Ampyra knockoffs
Acorda has suffered a fresh setback in its last-ditch attempt to stop a generic version of its multiple sclerosis drug Ampyra from hitting the market …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
